Source:http://linkedlifedata.com/resource/pubmed/id/16287242
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2005-11-18
|
pubmed:abstractText |
Most members of the tumor necrosis factor (TNF) ligand family occur in both a membrane-bound and a soluble form, which can possess differential bioactivities. The aim of this work was the construction of a synthetic-biological hybrid system consisting of chemically nanostructured core-shell particles with a diameter of 100 nm, 1 microm, or 10 microm and the cytokine TNF to obtain a tool that mimics the bioactivity of naturally occurring membrane-bound TNF. Synthetic core-shell nanoparticles consisting of an inorganic silica core and an ultrathin organic shell bearing a maleimide group at the shell surface which allowed for a covalent and site-directed coupling of CysHisTNF mutants were prepared. The TNF mutants were modified at the N-terminus by PCR cloning by introducing a His-Tag for purification and a free cysteine group for reaction with the particle-attached maleimide group. The resulting nanostructured hybrid particles initiated strong TNF receptor type 2 specific responses, otherwise only seen for the membrane-bound form of TNF, but not the soluble cytokine, thus clearly demonstrating new and membrane TNF-like properties of the bioconjugated soluble TNF.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Ligands,
http://linkedlifedata.com/resource/pubmed/chemical/Maleimides,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Tumor Necrosis Factor...,
http://linkedlifedata.com/resource/pubmed/chemical/Silicon Dioxide,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/maleimide
|
pubmed:status |
MEDLINE
|
pubmed:issn |
1043-1802
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
16
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1459-67
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:16287242-Animals,
pubmed-meshheading:16287242-Cell Line, Tumor,
pubmed-meshheading:16287242-Drug Design,
pubmed-meshheading:16287242-Humans,
pubmed-meshheading:16287242-Ligands,
pubmed-meshheading:16287242-Maleimides,
pubmed-meshheading:16287242-Membrane Proteins,
pubmed-meshheading:16287242-Mice,
pubmed-meshheading:16287242-Molecular Mimicry,
pubmed-meshheading:16287242-Mutation,
pubmed-meshheading:16287242-Nanostructures,
pubmed-meshheading:16287242-Particle Size,
pubmed-meshheading:16287242-Receptors, Tumor Necrosis Factor, Type II,
pubmed-meshheading:16287242-Silicon Dioxide,
pubmed-meshheading:16287242-Solubility,
pubmed-meshheading:16287242-Tumor Necrosis Factor-alpha
|
pubmed:articleTitle |
Tumor necrosis factor (TNF)-functionalized nanostructured particles for the stimulation of membrane TNF-specific cell responses.
|
pubmed:affiliation |
Institute of Cell Biology and Immunology, University of Stuttgart, Allmandring 31, D-70569 Stuttgart, Germany.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|